Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis
| العنوان: | Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis |
|---|---|
| المؤلفون: | Vicente Escudero-Vilaplana, Nicolás Trovato-López, Alberto Morell-Baladrón, Estefanía Alañón-Plaza, Esther Ramírez-Herráiz, María José Bellini, Ana Herranz-Alonso, María Sanjurjo-Sáez, José María Bellón-Cano |
| المصدر: | SEDICI (UNLP) Universidad Nacional de La Plata instacron:UNLP CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET Journal of Pharmacy & Pharmaceutical Sciences, Vol 15, Iss 3 (2012) Scopus-Elsevier |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Male, lcsh:RS1-441, Pharmaceutical Science, Receptors, Tumor Necrosis Factor, Etanercept, Arthritis, Rheumatoid, immune system diseases, Medicine, skin and connective tissue diseases, Antibodies, Monoclonal, purl.org/becyt/ford/3.1 [https], Middle Aged, Farmacia, Medicina Básica, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, Female, purl.org/becyt/ford/3 [https], Immunotherapy, medicine.drug, Adult, musculoskeletal diseases, medicine.medical_specialty, Farmacología y Farmacia, CIENCIAS MÉDICAS Y DE LA SALUD, Medicina, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, lcsh:Pharmacy and materia medica, Internal medicine, Adalimumab, Humans, Medical prescription, Aged, Retrospective Studies, Pharmacology, business.industry, Tumor Necrosis Factor-alpha, lcsh:RM1-950, Retrospective cohort study, medicine.disease, Infliximab, Surgery, Anti-tnf, lcsh:Therapeutics. Pharmacology, Immunoglobulin G, Observational study, business, Rheumatism |
| الوصف: | Purpose. To evaluate the association between starting early treatment with anti-TNF and effectiveness as well as the possibility of applying therapeutic spacing in daily practice in patients with rheumatoid arthritis (RA). Methods. Observational, retrospective study conducted in two universitary hospitals in Spain. RA patients who received the first anti-TNF (adalimumab: ADA, etanercept: ETN or infliximab: IFX) during the study period (October 2006-2010) were included. Demographic data, time since diagnosis, disease activity (DAS28-ESR) and anti-TNF dosage were analyzed. Therapeutic objective was defined as DAS28Results. 82 patients were included. The prescription profile was: ADA (48.8%), ETN (31.7%) and IFX (19.5%). 71.4% of patients treated with anti-TNF during the first year since diagnosis, 57.1% of those who started after 1-5 years and 30.6% of patients who started after 5 years were in remission when the study ended. De-escalation strategy was performed in 25.6% of patients: ETN (38.5%), ADA (20.0%) and IFX (18.8%). The patients treated with a higher dose according to label doses were: IFX (81%), ADA, (12.5%) and ETN (7.7%). Conclusions. Results suggest that early treatment with anti-TNF can achieve a higher percentage of remissions. Therapeutic spacing is established as a strategy that improves the efficiency in those patients in remission, being the ETN the anti-TNF most susceptible for spacing, although a relation between the early beginning with anti-TNF and the used dose was not found. Instituto de Investigaciones Bioquímicas de La Plata |
| وصف الملف: | application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134441cb329162507976c851567b7336Test http://sedici.unlp.edu.ar/handle/10915/96808Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....134441cb329162507976c851567b7336 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |